Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 64, Issue 7, Pages 3658-3676Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c01882
Keywords
-
Categories
Funding
- Wellcome Trust Seeding Drug Discovery Award [WT100544]
- Reviral Ltd.
- BBSRC [BBS/E/I/00001709] Funding Source: UKRI
Ask authors/readers for more resources
RV521, an orally bioavailable inhibitor of RSV fusion, demonstrated potent antiviral efficacy against various RSV strains and clinical isolates with efficient penetration into lung tissue. In human volunteers experimentally infected with RSV, RV521 showed a significant reduction in viral load and symptoms, highlighting its promising antiviral effects.
RV521 is an orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion that was identified after a lead optimization process based upon hits that originated from a physical property directed hit profiling exercise at Reviral. This exercise encompassed collaborations with a number of contract organizations with collaborative medicinal chemistry and virology during the optimization phase in addition to those utilized as the compound proceeded through preclinical and clinical evaluation. RV521 exhibited a mean IC50 of 1.2 nM against a panel of RSV A and B laboratory strains and clinical isolates with antiviral efficacy in the Balb/C mouse model of RSV infection. Oral bioavailability in preclinical species ranged from 42 to >100% with evidence of highly efficient penetration into lung tissue. In healthy adult human volunteers experimentally infected with RSV, a potent antiviral effect was observed with a significant reduction in viral load and symptoms compared to placebo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available